DK3507306T3 - Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer - Google Patents

Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer

Info

Publication number
DK3507306T3
DK3507306T3 DK17765002.5T DK17765002T DK3507306T3 DK 3507306 T3 DK3507306 T3 DK 3507306T3 DK 17765002 T DK17765002 T DK 17765002T DK 3507306 T3 DK3507306 T3 DK 3507306T3
Authority
DK
Denmark
Prior art keywords
stimulatory
binding
checkpoint receptors
immunomodulatory antibodies
bispecific immunomodulatory
Prior art date
Application number
DK17765002.5T
Other languages
Danish (da)
English (en)
Inventor
Matthew Bernett
Gregory Moore
John Desjarlais
Michael Hedvat
Christine Bonzon
Umesh S Muchhal
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/623,314 external-priority patent/US10787518B2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority claimed from PCT/US2017/049497 external-priority patent/WO2018045110A1/en
Application granted granted Critical
Publication of DK3507306T3 publication Critical patent/DK3507306T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK17765002.5T 2016-08-30 2017-08-30 Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer DK3507306T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381239P 2016-08-30 2016-08-30
US201762456033P 2017-02-07 2017-02-07
US201762479723P 2017-03-31 2017-03-31
US15/623,314 US10787518B2 (en) 2016-06-14 2017-06-14 Bispecific checkpoint inhibitor antibodies
PCT/US2017/049497 WO2018045110A1 (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Publications (1)

Publication Number Publication Date
DK3507306T3 true DK3507306T3 (da) 2025-10-20

Family

ID=65632988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17765002.5T DK3507306T3 (da) 2016-08-30 2017-08-30 Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer

Country Status (12)

Country Link
EP (1) EP3507306B1 (cg-RX-API-DMAC7.html)
JP (2) JP7080219B2 (cg-RX-API-DMAC7.html)
KR (2) KR102575681B1 (cg-RX-API-DMAC7.html)
CN (1) CN110267990B (cg-RX-API-DMAC7.html)
AU (1) AU2017321625A1 (cg-RX-API-DMAC7.html)
CA (1) CA3035343A1 (cg-RX-API-DMAC7.html)
DK (1) DK3507306T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251424T1 (cg-RX-API-DMAC7.html)
IL (1) IL265046B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023006786A (cg-RX-API-DMAC7.html)
SG (1) SG11201901712YA (cg-RX-API-DMAC7.html)
ZA (1) ZA201901752B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3044323B1 (en) * 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Methods for detecting and quantifying host cell protein in cell lines
KR102170077B1 (ko) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
CN112996813A (zh) * 2018-10-31 2021-06-18 生物蛋白有限公司 抗ctla4抗体、抗体片段、其免疫结合物和其用途
AU2021257570A1 (en) * 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2023521228A (ja) * 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
CN116615442A (zh) * 2020-09-08 2023-08-18 优特力克斯有限公司 程序性细胞死亡1多肽变体
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
TWI605828B (zh) * 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
WO2012065055A2 (en) * 2010-11-12 2012-05-18 The Rockefeller University Fusion proteins for hiv therapy
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA3211863A1 (en) * 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
EP2951203B1 (en) * 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
US10544187B2 (en) * 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP3024851B1 (en) * 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
NZ720353A (en) * 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
EA201790834A1 (ru) * 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
EA038349B1 (ru) * 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
SG11201704274QA (en) * 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
PT3242890T (pt) * 2015-01-08 2019-12-10 Genmab As Agentes de ligação agonistas do recetor de tnf
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos

Also Published As

Publication number Publication date
JP7080219B2 (ja) 2022-06-03
CN110267990A (zh) 2019-09-20
JP2019529368A (ja) 2019-10-17
JP2022111148A (ja) 2022-07-29
CA3035343A1 (en) 2018-03-08
HRP20251424T1 (hr) 2025-12-19
MX2023006786A (es) 2023-06-20
AU2017321625A1 (en) 2019-04-04
IL265046B1 (en) 2024-12-01
KR102575681B1 (ko) 2023-09-08
CN110267990B (zh) 2023-11-07
RU2019109147A3 (cg-RX-API-DMAC7.html) 2021-01-22
KR20230130174A (ko) 2023-09-11
EP3507306A1 (en) 2019-07-10
KR20190044106A (ko) 2019-04-29
RU2019109147A (ru) 2020-10-05
ZA201901752B (en) 2020-09-30
IL265046B2 (en) 2025-04-01
IL265046A (en) 2019-04-30
SG11201901712YA (en) 2019-03-28
EP3507306B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
ZA202203250B (en) Cd3 binding antibodies
IL269531A (en) Improved antigen binding receptors
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
DK3328889T3 (da) Bispecifikke antistofkonstruktioner, der binder dll3 og cd3
DK3328892T3 (da) Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3
IL263840A (en) cd3 binding antibodies
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
DK3356411T3 (da) Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
DK3328893T3 (da) Bispecifikke antistofkonstruktioner, der binder mesothelin og cd3
DK3328888T3 (da) ANTI-PSMA-antistoffer, bispecifikke antigenbindingsmolekyler, der binder PSMA AND og CD3, samt anvendelser deraf
DK3592384T3 (da) Antistoffer, der specifikt binder til human il-1r7
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3097122T3 (da) Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
DK3558369T3 (da) Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
DK3583120T3 (da) Modificerede transferrinreceptorbindende polypeptider
DK3487882T3 (da) Anti-gprc5d-antistoffer, bispecifikke antigenbindende molekyler, der binder gprc5d og cd3, samt anvendelser deraf
DK3507306T3 (da) Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer
DK3122781T3 (da) Bispecifikke antistoffer, der binder til cd38 og cd3
DK3710484T5 (da) Ctla-4-bindende antistoffer og anvendelser deraf
LT3247725T (lt) Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
DK3665198T3 (da) Antistoffer, der binder egfr og cmet
IL274121A (en) Bispecific antibodies that bind ALK-1 and BMPR-2
DK3182999T3 (da) Anti-lag3-antistoffer og antigenbindingsfragmenter